Telomir Pharmaceuticals, Inc. (TELO)
- Previous Close
6.74 - Open
6.77 - Bid 6.24 x 100
- Ask 6.83 x 100
- Day's Range
5.90 - 6.86 - 52 Week Range
4.76 - 20.72 - Volume
23,888 - Avg. Volume
71,788 - Market Cap (intraday)
203.271M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
telomirpharma.comRecent News: TELO
Compare To: TELO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TELO
Valuation Measures
Market Cap
203.27M
Enterprise Value
203.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
59.12
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-17.79
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-102.18%
Return on Equity (ttm)
-1,045.36%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-13.07M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
1.23k
Total Debt/Equity (mrq)
18.28%
Levered Free Cash Flow (ttm)
-1.96M